# EDGAR Filing Document

**Accession Number:** 0001757064
**File Stem:** 0001171843-25-004368
**Filing Date:** 2025-7
**Character Count:** 21528
**Document Hash:** 9616c7e39dcac90ffc8aa332e41f946a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-004368.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001171843-25-004368

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250708

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genfit S.A.
- **CENTRAL INDEX KEY:** 0001757064
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38844
- **FILM NUMBER:** 251111154

**BUSINESS ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120
- **BUSINESS PHONE:** 33 3 20 16 4000

**MAIL ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report: July 8, 2025**

**Commission File Number: 001-38844**

## GENFIT S.A.
**(Translation of registrant's name into English)** 

**Parc Eurasanté**

**885, avenue Eugène Avinée**

**59120 Loos, France**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**EXHIBIT LIST**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](exh_991.htm) | [Press Release dated July 8, 2025.](exh_991.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GENFIT S.A.** | **GENFIT S.A.** |
| Date: July 8, 2025 | By: | /s/ Pascal PRIGENT |
|  |  | Name: Pascal PRIGENT |
|  |  | Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](hdr.jpg)

**GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial**

**Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025** **- GENFIT (Nasdaq and Euronext: GNFT)**, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· 201,100 shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· €398 484.67

During the first half of 2025, total trading was:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· On the buy side: 1 412,901 shares for a total amount of €5,016,550.43

· On the sell side: 1 419,301 shares for a total amount of €5,061,074.96

During this same period, the number of trades were:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· On the buy side: 2,673

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· On the sell side: 1,894

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· 27, 911 shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· €769 849,43

**ABOUT GENFIT**

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on- Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>1</sub>

![](hdr.jpg)

**FORWARD LOOKING STATEMENTS**

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT's research and development programs. The use of certain words, such as "believe", "potential", "expect", "target", "may", "will", "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

**CONTACTS**

**GENFIT** \| Investors

Tel: +33 3 2016 4000 \| investors@genfit.com

**GENFIT** \| Media

Stephanie Boyer – Press relations \| Tel: +333 2016 4000 \| stephanie.boyer@genfit.com

<sup>1</sup> Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®.

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>2</sub>

![](hdr.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPENDIX <br> H1 2025 |
|  | **Buy side** | **Buy side** | **Buy side** | **Sell-** **side** | **Sell-** **side** | **Sell-** **side** |
| <br> **Date** | **Number** **of executio ns** | &nbsp;&nbsp;&nbsp;&nbsp;**Number of shares** | &nbsp;&nbsp;**Traded amounts in EUR** | **Number** **of executio ns** | &nbsp;&nbsp;&nbsp;&nbsp;**Number of shares** | &nbsp;&nbsp;**Traded amounts in EUR** |
| **TOTAL** | **2 673** | **1 412 901** | **5 016 55043** | **1 894** | **1 419 301** | **5 061 07496** |
| 02/01/20<br> 25 | 18 | 7501 | 26 67603 | 39 | 31501 | 113 12608 |
| 03/01/20<br> 25 | 28 | 13001 | 46 60872 | 14 | 8721 | 31 25929 |
| 06/01/20<br> 25 | 28 | 8001 | 28 81112 | 12 | 8281 | 29 92803 |
| 07/01/20<br> 25 | 32 | 10501 | 37 43365 | 10 | 3641 | 13 18402 |
| 08/01/20<br> 25 | 31 | 10001 | 34 88859 | 16 | 5692 | 19 85318 |
| 09/01/20<br> 25 | 16 | 6387 | 22 06779 | 20 | 14056 | 48 95691 |
| 10/01/20<br> 25 | 38 | 11458 | 39 74952 | 12 | 6458 | 22 76600 |
| 13/01/20<br> 25 | 23 | 14422 | 48 54041 | 6 | 2369 | 7 88886 |
| 14/01/20<br> 25 | 26 | 11900 | 39 65532 | 7 | 6554 | 22 25358 |
| 15/01/20<br> 25 | 8 | 4170 | 13 77547 | 15 | 8427 | 27 95944 |
| 16/01/20<br> 25 | 19 | 10283 | 34 36784 | 12 | 11643 | 39 16903 |
| 17/01/20<br> 25 | 8 | 4501 | 15 04833 | 13 | 8901 | 29 89285 |
| 20/01/20<br> 25 | 17 | 11722 | 39 28370 | 52 | 29101 | 100 88706 |
| 21/01/20<br> 25 | 28 | 12501 | 43 01357 | 17 | 8504 | 29 27893 |
| 22/01/20<br> 25 | 8 | 7501 | 25 86345 | 15 | 17501 | 60 47856 |
| 23/01/20<br> 25 | 5 | 3463 | 11 78002 | 8 | 3463 | 11 94735 |
| 24/01/20<br> 25 | 67 | 20501 | 70 50847 | 14 | 17501 | 61 07849 |
| 27/01/20<br> 25 | 25 | 9424 | 32 13980 | 6 | 6001 | 20 59843 |
| 28/01/20<br> 25 | 7 | 4576 | 15 74149 | 13 | 12424 | 4305972 |
| 29/01/20<br> 25 | 24 | 13501 | 47 98093 | 31 | 32076 | 114 58798 |
| 30/01/20<br> 25 | 28 | 22901 | 82 74818 | 41 | 22901 | 85 28859 |

---

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>3</sub>

![](hdr.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| 31/01/20<br> 25 | 28 | 21001 | 75 76363 | 12 | 11001 | 4039369 |
| 03/02/20<br> 25 | 25 | 8001 | 28 28305 | 17 | 12001 | 42 55099 |
| 04/02/20<br> 25 | 6 | 4001 | 14 28861 | 29 | 15129 | 54 63581 |
| 05/02/20<br> 25 | 5 | 4501 | 16 46367 | 15 | 13873 | 51 37893 |
| 06/02/20<br> 25 | 2 | 1001 | 3 80382 | 17 | 17501 | 66 75879 |
| 07/02/20<br> 25 | 18 | 21001 | 79 00891 | 4 | 1001 | 3 82382 |
| 10/02/20<br> 25 | 6 | 2001 | 7 52376 | 15 | 11001 | 41 88378 |
| 11/02/20<br> 25 | 28 | 9001 | 33 71379 | 6 | 9001 | 33 97878 |
| 12/02/20<br> 25 | 18 | 10001 | 37 56376 | 14 | 20001 | 75 98380 |
| 13/02/20<br> 25 | 18 | 8001 | 30 92258 | 16 | 9001 | 35 27393 |
| 14/02/20<br> 25 | 46 | 15533 | 60 44434 | 10 | 6033 | 23 61401 |
| 17/02/20<br> 25 | 46 | 29501 | 112 15897 | 21 | 13001 | 51 03894 |
| 18/02/20<br> 25 | 15 | 5001 | 18 85377 | 1 | 1 | 376 |
| 19/02/20<br> 25 | 44 | 22501 | 83 67379 | 1 | 1 | 377 |
| 20/02/20<br> 25 | 24 | 11501 | 42 09516 | 4 | 4001 | 14 79366 |
| 21/02/20<br> 25 | 17 | 6001 | 22 23364 | 8 | 9001 | 33 65366 |
| 24/02/20<br> 25 | 28 | 12626 | 46 52618 | 11 | 5126 | 19 16247 |
| 25/02/20<br> 25 | 27 | 14501 | 52 15647 | 3 | 1501 | 5 44866 |
| 26/02/20<br> 25 | 40 | 12501 | 44 13528 | 3 | 1501 | 5 41858 |
| 27/02/20<br> 25 | 34 | 13501 | 47 09594 | 9 | 3001 | 10 59350 |
| 28/02/20<br> 25 | 18 | 8001 | 27 67098 | 14 | 8001 | 27 90845 |
| 03/03/20<br> 25 | 17 | 7927 | 27 61814 | 6 | 4501 | 15 85851 |
| 04/03/20<br> 25 | 56 | 27575 | 93 60775 | 1 | 1 | 348 |
| 05/03/20<br> 25 | 12 | 5001 | 16 95339 | 8 | 6001 | 20 58337 |
| 06/03/20<br> 25 | 14 | 6001 | 20 52654 | 17 | 12501 | 43 15845 |
| 07/03/20<br> 25 | 19 | 9501 | 32 68049 | 9 | 12001 | 41 52346 |
| 10/03/20<br> 25 | 22 | 10390 | 35 33410 | 6 | 2390 | 8 30219 |
| 11/03/20<br> 25 | 30 | 17873 | 60 36284 | 12 | 7612 | 26 43716 |

---

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>4</sub>

![](hdr.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| 12/03/20<br> 25 | 18 | 6018 | 20 28559 | 14 | 9262 | 31 57249 |
| 13/03/20<br> 25 | 19 | 12974 | 43 53309 | 14 | 10491 | 35 67087 |
| 14/03/20<br> 25 | 14 | 11501 | 38 11086 | 9 | 11658 | 38 78955 |
| 17/03/20<br> 25 | 8 | 4501 | 14 93832 | 13 | 12344 | 41 02714 |
| 18/03/20<br> 25 | 6 | 2001 | 6 74335 | 6 | 12001 | 40 66083 |
| 19/03/20<br> 25 | 5 | 4833 | 16 15392 | 9 | 4833 | 16 27005 |
| 20/03/20<br> 25 | 16 | 6395 | 21 31984 | 8 | 2895 | 9 70468 |
| 21/03/20<br> 25 | 21 | 11715 | 39 00228 | 24 | 23001 | 78 60086 |
| 24/03/20<br> 25 | 20 | 9001 | 30 09196 | 10 | 9443 | 31 88741 |
| 25/03/20<br> 25 | 17 | 15731 | 52 69838 | 12 | 7002 | 23 69407 |
| 26/03/20<br> 25 | 29 | 15500 | 51 26253 | 6 | 7501 | 24 94833 |
| 27/03/20<br> 25 | 8 | 9001 | 30 11582 | 22 | 27001 | 90 98824 |
| 28/03/20<br> 25 | 26 | 5999 | 20 29906 | 21 | 13501 | 45 90340 |
| 31/03/20<br> 25 | 18 | 12003 | 39 73005 | 14 | 7957 | 26 31133 |
| 01/04/20<br> 25 | 21 | 19430 | 63 90896 | 24 | 17930 | 59 73917 |
| 02/04/20<br> 25 | 20 | 10501 | 34 21079 | 1 | 1 | 330 |
| 03/04/20<br> 25 | 11 | 3749 | 12 14301 | 6 | 7102 | 23 24776 |
| 04/04/20<br> 25 | 55 | 26310 | 82 97069 | 3 | 1501 | 4 83327 |
| 07/04/20<br> 25 | 24 | 13987 | 38 87547 | 15 | 15287 | 46 15191 |
| 08/04/20<br> 25 | 10 | 6001 | 18 79813 | 12 | 21701 | 69 00397 |
| 09/04/20<br> 25 | 22 | 19301 | 59 19018 | 28 | 16655 | 49 24101 |
| 10/04/20<br> 25 | 23 | 18647 | 54 48597 | 28 | 18147 | 57 87623 |
| 11/04/20<br> 25 | 12 | 6001 | 17 76296 | 35 | 22147 | 65 89065 |
| 14/04/20<br> 25 | 1 | 1 | 303 | 14 | 21501 | 66 12805 |
| 15/04/20<br> 25 | 8 | 3501 | 10 90309 | 8 | 14501 | 45 60811 |
| 16/04/20<br> 25 | 7 | 4013 | 12 51542 | 8 | 4013 | 12 56575 |
| 17/04/20<br> 25 | 31 | 14001 | 43 38714 | 2 | 1501 | 4 65913 |
| 22/04/20<br> 25 | 16 | 8501 | 26 05905 | 19 | 13501 | 41 69703 |

---

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>5</sub>

![](hdr.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| 23/04/20<br> 25 | 9 | 9501 | 29 89404 | 22 | 29501 | 92 55113 |
| 24/04/20<br> 25 | 21 | 12501 | 39 92982 | 10 | 9001 | 29 00419 |
| 25/04/20<br> 25 | 19 | 9001 | 29 00626 | 22 | 11001 | 3588922 |
| 28/04/20<br> 25 | 15 | 6501 | 21 53827 | 17 | 13501 | 4507525 |
| 29/04/20<br> 25 | 12 | 9001 | 31 23941 | 26 | 23984 | 83 72335 |
| 30/04/20<br> 25 | 26 | 24000 | 8577696 | 16 | 17927 | 64 25073 |
| 02/05/20<br> 25 | 24 | 15388 | 56 85050 | 38 | 23913 | 88 31908 |
| 05/05/20<br> 25 | 2 | 1501 | 598879 | 28 | 25237 | 10135255 |
| 06/05/20<br> 25 | 17 | 10501 | 41 67406 | 35 | 28830 | 115 99635 |
| 07/05/20<br> 25 | 15 | 10001 | 39 74107 | 6 | 2501 | 9 97912 |
| 08/05/20<br> 25 | 42 | 14950 | 5860265 | 10 | 4501 | 17 71598 |
| 09/05/20<br> 25 | 37 | 22103 | 87 13224 | 15 | 15052 | 60 10203 |
| 12/05/20<br> 25 | 21 | 13501 | 51 57990 | 19 | 13501 | 52 40494 |
| 13/05/20<br> 25 | 22 | 12001 | 46 12992 | 3 | 2001 | 7 73989 |
| 14/05/20<br> 25 | 8 | 6001 | 22 74685 | 37 | 29501 | 112 69677 |
| 15/05/20<br> 25 | 42 | 23501 | 86 60448 | 8 | 5001 | 18 72474 |
| 16/05/20<br> 25 | 27 | 12001 | 44 61552 | 28 | 18001 | 67 12465 |
| 19/05/20<br> 25 | 33 | 25063 | 9316719 | 15 | 10584 | 39 78938 |
| 20/05/20<br> 25 | 1 | 1 | 371 | 25 | 23480 | 89 98381 |
| 21/05/20<br> 25 | 9 | 7312 | 2934796 | 44 | 32312 | 130 85875 |
| 22/05/20<br> 25 | 16 | 8001 | 32 21883 | 24 | 12001 | 48 70702 |
| 23/05/20<br> 25 | 51 | 44001 | 172 31672 | 1 | 1 | 405 |
| 26/05/20<br> 25 | 17 | 12002 | 46 39073 | 11 | 6001 | 23 36189 |
| 27/05/20<br> 25 | 22 | 12411 | 47 97820 | 6 | 3412 | 13 35883 |
| 28/05/20<br> 25 | 23 | 10004 | 38 37534 | 21 | 13001 | 50 15383 |
| 29/05/20<br> 25 | 23 | 17000 | 66 75798 | 29 | 29001 | 113 57778 |
| 30/05/20<br> 25 | 13 | 6501 | 2574494 | 32 | 17018 | 67 62817 |
| 02/06/20<br> 25 | 21 | 11001 | 43 78805 | 9 | 7001 | 27 83003 |

---

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>6</sub>

![](hdr.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| 03/06/20<br> 25 | 11 | 9016 | 35 77594 | 23 | 17501 | 69 70508 |
| 04/06/20<br> 25 | 23 | 15501 | 60 72098 | 18 | 11001 | 43 47001 |
| 05/06/20<br> 25 | 32 | 25900 | 100 37441 | 26 | 18300 | 71 21665 |
| 06/06/20<br> 25 | 46 | 17768 | 67 09854 | 1 | 1 | 383 |
| 09/06/20<br> 25 | 12 | 4010 | 14 92759 | 20 | 11877 | 44 73258 |
| 10/06/20<br> 25 | 6 | 3115 | 11 76797 | 22 | 10106 | 38 56106 |
| 11/06/20<br> 25 | 10 | 6992 | 26 46773 | 17 | 7001 | 26 58581 |
| 12/06/20<br> 25 | 38 | 13001 | 48 92172 | 6 | 3001 | 11 28979 |
| 13/06/20<br> 25 | 40 | 16740 | 61 24664 | 14 | 7168 | 26 35258 |
| 16/06/20<br> 25 | 20 | 12001 | 43 55163 | 9 | 5501 | 20 14565 |
| 17/06/20<br> 25 | 11 | 6439 | 23 06199 | 17 | 11011 | 39 68353 |
| 18/06/20<br> 25 | 31 | 12001 | 42 70316 | 4 | 3001 | 10 77659 |
| 19/06/20<br> 25 | 40 | 17001 | 59 35763 | 4 | 3001 | 10 44654 |
| 20/06/20<br> 25 | 24 | 13501 | 46 65649 | 7 | 6001 | 20 96143 |
| 23/06/20<br> 25 | 13 | 9001 | 30 05731 | 30 | 21001 | 70 40732 |
| 24/06/20<br> 25 | 9 | 5001 | 16 96939 | 3 | 2001 | 6 80340 |
| 25/06/20<br> 25 | 19 | 10001 | 33 48535 | 10 | 4001 | 13 60940 |
| 26/06/20<br> 25 | 4 | 1001 | 3 32732 | 35 | 19001 | 63 97732 |
| 27/06/20<br> 25 | 30 | 15530 | 51 76413 | 14 | 9530 | 32 00822 |
| 30/06/20<br> 25 | 33 | 10851 | 35 52943 | 10 | 6751 | 22 14929 |

---

**GENFIT** \| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE \| +333 2016 4000 \| www.genfit.com<sub>7</sub>